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Abciximab Usage in Percutaneous Coronary Intervention in HighRisk Patients: Early and Late Outcomes
ANNA CHAN, WILSON CHAN, CHUN-WAI CHIU, CHI-CHIU KUM, KAM-SANG WOO, JOHN E SANDERSON
From Department of Medicine, The Chinese University of Hong Kong, Hong Kong
CHAN ET AL.: Abciximab Usage in Percutaneous Coronary Intervention in High-Risk Patients: Early and Late
Outcomes. Background: Clinical adverse cardiac events have been significantly reduced by the adjunctive usage of
Glycoprotein IIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary intervention (PCI). However,
no information on its safety and efficacy is available for Asian. Methods: All patients who had PCI together with
abciximab in the Prince of Wales Hospital from August 1998 to December 2000 were included. Hospital records,
ECG records and laboratory results were reviewed retrospectively. The primary composite endpoint including death,
myocardial infarction, target vessel revascularization or bypass surgery was assessed at index hospitalization, at 1
month, and 6 months after PCI. The safety of abciximab and any difference in outcomes between the prophylactic
and standby group were studied. Results: One hundreds and five patients had PCI together with abciximab during
the study period. All received bolus abciximab of 0.25 mg/kg followed by 0.125 µg/kg/min infusion over 12 hours.
Twenty-one patients had experienced the primary endpoint at the index hospitalization (7 from the prophylactic
group and 14 from the standby group). Additional 3 patients in the prophylactic group had reached primary endpoint
at 1 month. At 6 months, another 1 in the prophylactic group and 4 in the standby group reached primary endpoint.
Total 5 deaths occurred during the index hospitalization, 2 from prophylactic group and 3 from standby group. The
bleeding complication was similar in both groups and most of them were minor bleeding only. Three patients had
severe thrombocytopenia (platelet count less than 20x109/l) and total 6 patients had thrombocytopenia of <50x109/l.
Conclusion: There was a trend towards better clinical outcome in the abciximab prophylactic group and the benefit
seemed to be sustained at 6 months. Low incidence of major bleeding was observed in the usage of abciximab, but the
incidence of thrombocytopenia after abciximab usage in Chinese was much higher than reported in current published
studies. (J HK Coll Cardiol 2001;9:171-175)
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Introduction

Methods

Several large clinical trials published in recent
years have demonstrated the efficacy of Glycoprotein
IIb/IIIa (GP IIb/IIIa) receptor inhibitors in preventing
ischaemic complications associated with PCI.1-4 One of
the proposed mechanisms for ischaemic complications
is due to mechanical vessel endothelial damage which
triggers platelet activation and aggregation. GP IIb/IIIa
receptor inhibitors acting as potent inhibitors in the final
common pathway of platelet aggregation will inhibit
the above adverse platelet mediated thrombotic process.
However, the usage of GP IIb/IIIa receptor inhibitors
in Hong Kong has been limited. Apart from financial
considerations as the drug is expensive, the other
concern is the safety profile of the drug in Chinese as
most of the data are from Western studies. Therefore,
GP IIb/IIIa receptor inhibitors are often used as
“standby” therapy i.e. administered when complications
or unfavorable angiographic results were encountered
during PCI in Hong Kong. We evaluated the usage of
abciximab – a GP IIb/IIIa receptor inhibitor for PCI in
high-risk patients in relation to the early and late
outcomes, in particular efficacy difference between the
prophylactic and standby strategies. The safety profile
and bleeding risk were also determined.

All patients who had PCI together with abciximab
in Prince of Wales Hospital from August 1998 to
December 2000 were included. This was a retrospective
study of total 105 patients in a single center. The study
population was divided into prophylactic group –
abciximab given before intervention, or standby group
– abciximab given during intervention when
complications or suboptimal angiographic results were
encountered. Fifty-four were from the prophylactic
group and 51 were from the standby group. All hospital
records, ECG records and laboratory results were
reviewed. The primary composite endpoint of death,
myocardial infarction, target vessel revascularization
or bypass surgery was assessed at index hospitalization,
at 1 month and 6 months after PCI. Post-procedural
diagnosis of MI was made if CK/CKMB was elevated
two times the baseline or there were new ECG changes.

Study Population
Table 1 shows the baseline demographic
characteristic of patients. Male predominates in both
study groups. The baseline characteristics including risk

Table 1. Baseline characteristics of patients (N=105)
Characteristic
Male gender
Mean age (year)
Weight (kg)
Height (cm)
Smoking
DM
HT
Prior MI
Prior PCI
Prior CABG
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Prophylactic group
76.9%
62.4
66.6
163.0
78.8%
26.9%
46.2%
7.7%
9.6%
5.8%

Standby group
73.7%
74.1
61.9
160.6
54.4%
12.3%
33.3%
8.8%
14.0%
8.8%
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P valve
NS
NS
0.03
NS
NS
NS
NS
NS
NS
NS
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factors were similar in both groups except patients in
the prophylactic group had a higher body weight (p=
0.03).
All were high-risk patients as they either
presented with unstable angina (23.1% vs 31.6 %), postMI angina (26.9% vs 40.3%), direct or salvage PTCA
for acute myocardial infarction (23.0% vs 3.5%) in the
prophylactic and standby group respectively. A higher
percentage of patients in the prophylactic group had
primary or salvage PCI for acute myocardial infarction
than standby group (P=0.04). In setting like acute MI,
abciximab is often given “prophylactically” before
intervention in order to reduce ischaemic complications.
Standby abciximab was given to those with unexpected
suboptimal angiographic results after PCI. The main
reasons for standby usage of abciximab were presence
of thrombus (45.9%), slow flow (15.6%), dissection
(11%) or abrupt vessel closure (4.6%) on angiogram
during PCI.

Medication Regime
All patients received aspirin and intravenous
conjunctive weight adjusted dose of heparin (average
84 units/kg in prophylactic group and 111 units/kg in
the standby group) before or during procedure.
Additional ticlodipine (500 mg loading before PCI then
250 mg QD for 4 weeks) or clopidogrel (300 mg loading
before PCI then 75 mg QD for 4 weeks) were given
with coronary stenting. Seventy-five percent were on
beta blockers, 39% on ACEI, 47% on statins, indicating
most patients were on optimal medical therapy.
Abciximab was given as a bolus of 0.25 mg/kg followed
by 0.125 µg/kg/min infusion over 12 hours. The mean
heparin dose was statistical significantly lower in the
prophylactic group than in the standby group (5590 units
in the prophylactic group vs 6870 units in the standby
group, P<0.05). Lower doses of heparin were given in
the prophylactic group because of the concern of
excessive bleeding risk associated with the conjunctive
usage of abciximab and standard dose of heparin.
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Study Endpoints
All primary endpoints were classified by
reviewing hospital records. Serial ECG and cardiac
enzymes CPK and CKMB were monitored 8 hourly for
24 hours after PCI. Post-procedural diagnosis of MI was
made if CK/CKMB was elevated two times the baseline
or there were new ECG changes. Haematologic profiles
such as haemoglobin level and platelet counts were
monitored at 0 hour, 8 hourly for 24 hours and on day
of discharge. Thrombocytopenia was confirmed with
film comment to avoid pseudothrombocytopenia.

Results
Twenty-one patients experienced the primary
composite endpoints during the index hospitalization,
7 from the prophylactic group and 14 from the standby
group. The difference was mainly due to the reduction
of non-Q MI 5,6 in the prophylactic group (5.8% vs
19.3%, P<0.05). A total 5 deaths occurred during the
index hospitalization, 2 from prophylactic group and 3
from standby group. Most of deaths were from critically
ill patients who presented with acute myocardial
infarction or cardiogenic shock before intervention. An
additional 3 patients in the prophylactic group had
reached primary endpoint at 1 month. At 6 months, 1 in
the prophylactic group and 4 in the standby group
reached primary endpoint. The primary endpoint at 1
and 6 months were mainly due to target vessel
revascularization.
The bleeding complication was similar in both
groups despite the difference in conjunctive heparin
dosage. The overall bleeding risk was 20.2% and was
comparable with other studies. No serious clinical
bleeding such as intracerebral haemorrhage or bleeding
resulting in death was observed. Most bleeding
complications were mild and majority were local
complications such as groin haematoma or gum
bleeding. But 3.7% of patients did have gastrointestinal
bleeding and half of them requiring blood transfusions.
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Three patients had severe thrombocytopenia
(platelet count less than 20x109/l) and total 6 patients
had thrombocytopenia of platelet count less than 50x109/l.
All thrombocytopenia occurred within 24 hours after
administration of abciximab. The platelet count
recovered promptly usually within 24 hours to 48 hours
after stopping the infusion.

The onset is known to be very early and prompt recovery
is expected once the agent is stopped. The incidence of
severe thrombocytopenia appears to be significantly
higher in Hong Kong Chinese than reported in current
published studies.
No hypersensitivity or anaphylactic reactions
were noted after abciximab administration.

Discussion

Study Limitations

In this study, the overall clinical event rate is
substantial in both groups (total 27.6% reached primary
endpoints at 6 months). This was because our study
populations mainly included high-risk patients whom
were expected to have high mortality even with
intervention. They were sicker patients presented with
acute myocardial infarction and failed thrombolysis or
with cardiogenic shock. Still, the clinical adverse events
were reduced with usage of abciximab in the
prophylactic group when compared to standby group
(20.3% vs 35.3% respectively).
The potential usage of standby abciximab for
PCI-related complications justified further evaluation.
The delay administration of abciximab in standby
strategy still found to be useful might be due to the rapid
and persistent systemic inhibition of platelet inhibition.
Subgroup analysis of abciximab efficacy needs
exploration, though some studies suggested the benefit
is independent of device or modality used.
Determination of optimal conjunctive heparin
dose is important in order to maintain the efficacy of
anticoagulation without concomitant increase in
excessive bleeding risk. Heparin dose can either be
weight-adjusted or guided by activated clotting time to
achieve the optimal intensity of anticoagulation during
PCI. From our limited experience, a standby strategy
in presence of full systemic heparinization is not
associated with excessive bleeding risk. From our data,
the usage of closer device did not reduce the rate of
local vascular complications but did improve patient
comfort and allow early mobilization. Other
anticoagulation options like the use of GP IIb/IIIa
receptor inhibitors in combination with direct thrombin
inhibitor or thrombolytic agents in PCI or in acute
coronary syndrome needs further evaluation.
The risk of profound thrombocytopenia is
reported to be rare (0.4% to 1%) in previous studies.7

The limitation of study was small sample size
and was retrospective in nature and patients were not
randomized to one of prophylactic or standby group.
Nevertheless, our study reflects the daily clinical
practice in our center.
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Conclusion
The additional use of GP IIb/IIIa receptor
inhibitors in prophylactic group tends to have lower
ischaemia complications, particularly in the reduction
of non-Q myocardial infarction when compared with
bailout group. There was a trend towards better clinical
outcome in the prophylactic group and the benefit
seemed to be sustained at 6 months. Low incidence of
major bleeding was observed in the usage of abciximab
in Chinese. Further assessment of the cost-effectiveness
of standby strategy is important.
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